Browsing for next random stock pick!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
KWK - Currently don't see any resistance for this to not hit $1.46.
APT - Watch it closely here. <Link Back>
EVRY caught me off guard this morning lol. Oh well BIG TIME>
CPRX - Reflecting back here. <Link Back> Am still holding this but looks like it's time for some sparkles.
APT SPEX EVRY KWK & OPTT all on look out for me.
$2.69 next break out at least a little above $2.69 will be break out here IMO. Next target $2.90-$3. Yupe yupe but I could be wrong with my chart read lol
Nice call Smitter. $2.60 is good until next ride up!
INVT - Looks like I sell other half today. Looking good this morn to hit target <link back>
INVT - Wow $2.24 better than expected <LinkBack> Still target is $2.60 as long at it can move around $2.18s-$2.20. Took half position out already. Keeping some for the ride.
INVT where's my $2.18 hmmm
MSTX - Hmm..wondering if now is a good time.
OPTT - Now might be a good time to get on-board $1.30, hit $1.38 then first target $1.61 (that's the plan anyways)
SYMX - Nice move upward from $1.17 entry point here. $1.32 do-able IMO.
INVT - Nice move this morning. $2.04 from here with potential $2.60.
SPEX might be ready here for Sept coming as patent litigation deadlines getting close...just a feeling. $1.50 average is where I want to be now.
KWK - So far showing holding strong with closing today after break. Let's see next 48 hours though if slide back or any weaknesses.
KWK - Break out mode now that it's above $1.22. Target 1.46 - $1.55 give or take.
EDAP - Let's see if it can break out above $1.85 here. Look out for this b/c it might bounce right up into $2.01 then $2.14.
SYMX & NQ on watch for today with Azy.
LAYN - Looks like break out was confirmed @ above $11.19..just noticed lol.
Hang in there bro! Things will look better! What are you holding onto now?
Looks like our APT did better than expected with previous target $2.56. Let's see how it holds up today! Cheers!
Very nice flip TerribleTwit! Need to find some good flippers now that am back.
Indeed was a nice pop. Looks like long haul with this one for me.
Thanks RealGenius BTW RGDO did good yest. But still needs to break that $3 I guess.
Back in business! Went out to Chincoteague beach island for a bit to relax.
BOARD: I will be gone next week on a min-vaca. Taking time off with the market etc and re-think trading strategies. Good luck with trading next week everyone!
INVT - Very nice move up on a Friday <link back>
APT - Break out happened at above $2.38 target $2.56 within reach. Be safe exit $2.50. Hey it's Friday you never know.
BLFS - Moving back up nicely indeed
BLFS - Ouch this morning.
TKMR - Just great, Tekmira: FDA Enables Potential Use Of TKM-Ebola In Ebola-infected, Stock Surges
APT - I am paying this a revisit. Found my old post ref. http://investorshub.advfn.com/boards/read_msg.aspx?message_id=95642821
Looks like I am back again here Smitter! Big thanks to Xanadu here for reaching out to remind me of what I've missed.
DRNA - Dicerna Provides Operational Update and Reports Second Quarter 2014 Financial Results ref. http://finance.yahoo.com/news/dicerna-provides-operational-reports-second-200100592.html
BLFS - Q2 2014 Financial Highlights
Core product revenue was $2.2 million for the six months ended June 30, 2014, an increase of 29% over the same period in 2013. For the second quarter, core product revenue was $1.1 million, an increase of 14% over the second quarter of 2013, with increased sales to the regenerative medicine market and cell suppliers. Total revenue for the second quarter of 2014 was $1.2 million, a decrease of 48% compared to the second quarter of 2013 due to the cancellation of our contract manufacturing services agreement with an organ preservation company.
Gross margin for the quarter ended June 30, 2014 was 45%, compared to 35.6% in the same period in 2013, driven by the shift in mix toward the Company's more profitable core products in 2014.
Net loss for the second quarter of 2014 increased to $883,356, compared to a loss of $282,506 in the second quarter of 2013 and $559,371 in the first quarter of 2014. The increase in the loss is partially the result of increased expenditures in sales and marketing and G&A to support expansion of the core business and contract manufacturing services.
Mike Rice, BioLife's President & CEO, said, "Second quarter results marked our fourth consecutive quarter of core product revenue of over $1 million reflecting broader adoption of our products in our core regenerative medicine and cell supplier markets. Our primary focus for the rest of the year will be to support the of expansion of our core business and the successful launch of biologistexSM, a cloud-based information service for smart, controlled temperature containers for cells and tissues. We believe biologistex is highly complementary with our proprietary biopreservation media products and greatly strengthens our position as a critical tools provider to the markets we serve. We expect to launch biologistex in the fourth quarter of this year."
Achievements for the Second Quarter of 2014
We announced the execution of a long-term contract manufacturing services agreement with biotechnology company Somahlution LLC, in July 2014. We will manufacture DuraGraft™, a tissue preservation solution for storage of harvested veins used in coronary artery bypass graft (CABG) and other vascular access surgeries. We expect to start generating revenue from this new customer in the fourth quarter of 2014.
TxCell, a French biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announced the adoption of BioLife's CryoStor clinical grade cell freezing media for use in their European phase IIb clinical trial of Ovasave® immunotherapy for Crohn's Disease which is planned to start in the second half of 2014.
We received the Frost & Sullivan 2014 Technology Innovation Leadership Award for Biopreservation Media, recognizing our position as a market leader.
The Company will host a conference call and live webcast at 4:30 p.m. EDT this afternoon. To access the webcast, log on to the Investor Relations page of the BioLife Solutions website at www.biolifesolutions.com. Alternatively, you may access the live conference call by dialing (844) 825-0512 (U.S. & Canada) or (315) 625-6880 (International) with the following Conference ID: 82507281. A webcast replay will be available approximately two hours after the call and will be archived on www.biolifesolutions.com for 90 days.
ref. http://finance.yahoo.com/news/biolife-solutions-announces-second-quarter-200500367.html
BLFS - So far the report is good IMO.
EDAP - Look for entry closer to $1.23 (if it get's close)
EDAP - Well the breakdown below $1.56 has been warned <link back> Now we look out for the bottom. EDAP has been consistent with $3s (history) and I would take on a LONG position give it a month to spring back up.
DRWI - Stable moving right now. Take sometime and will not expect immediate POP. <link back>